Charles River Laboratories International, Inc. (NYSE:CRL)‘s stock had its “neutral” rating restated by research analysts at Credit Suisse Group in a research note issued to investors on Monday, The Fly reports. They presently have a $112.00 price target on the medical research company’s stock, up from their previous price target of $95.00. Credit Suisse Group’s price objective suggests a potential downside of 0.81% from the company’s current price.

CRL has been the subject of a number of other reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $120.00 price target on shares of Charles River Laboratories International in a report on Tuesday, September 12th. Zacks Investment Research raised Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 price target for the company in a report on Thursday, August 10th. Royal Bank Of Canada started coverage on Charles River Laboratories International in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 price target for the company. BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 22nd. Finally, Robert W. Baird reaffirmed a “buy” rating and issued a $114.00 price target on shares of Charles River Laboratories International in a report on Friday, September 1st. Six equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Charles River Laboratories International presently has an average rating of “Buy” and a consensus target price of $102.05.

Charles River Laboratories International (CRL) opened at 112.92 on Monday. Charles River Laboratories International has a 12 month low of $67.20 and a 12 month high of $113.83. The stock has a market capitalization of $5.37 billion, a price-to-earnings ratio of 29.75 and a beta of 0.96. The company has a 50 day moving average of $108.17 and a 200 day moving average of $98.26.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.07. The firm had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The firm’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same period in the prior year, the company posted $1.20 earnings per share. On average, equities analysts predict that Charles River Laboratories International will post $5.10 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/16/charles-river-laboratories-international-inc-crl-receives-neutral-rating-from-credit-suisse-group.html.

In other news, insider Davide Molho sold 6,165 shares of the stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $110.00, for a total value of $678,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Ross Smith sold 2,552 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the sale, the insider now directly owns 11,671 shares of the company’s stock, valued at $783,124.10. The disclosure for this sale can be found here. Insiders sold 18,699 shares of company stock valued at $1,892,393 over the last three months. Corporate insiders own 2.20% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in CRL. Quantbot Technologies LP raised its stake in shares of Charles River Laboratories International by 291.7% during the third quarter. Quantbot Technologies LP now owns 1,414 shares of the medical research company’s stock worth $117,000 after purchasing an additional 1,053 shares during the last quarter. Envestnet Asset Management Inc. raised its position in Charles River Laboratories International by 41.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,785 shares of the medical research company’s stock worth $135,000 after acquiring an additional 526 shares in the last quarter. Bessemer Group Inc. raised its position in Charles River Laboratories International by 2.3% in the fourth quarter. Bessemer Group Inc. now owns 1,933 shares of the medical research company’s stock worth $147,000 after acquiring an additional 43 shares in the last quarter. Tower Research Capital LLC TRC purchased a new position in Charles River Laboratories International in the third quarter worth $181,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Charles River Laboratories International by 12.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after acquiring an additional 202 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

The Fly

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.